By clicking "Allow," you will be taken to a website that is independent of ViiV Healthcare. The site you linking to is not controlled or endorsed by ViiV Healthcare, and ViiV Healthcare is not responsible for the content provided on that site.
This site is exclusively for healthcare professionals in the US. It contains medical information about ViiV Healthcare medications.
It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Preferences for Implementing Long-Acting Injectable Pre-Exposure Prophylaxis among Cisgender Men Who have Sex with Men in the US. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. Oral Presentation.
Variation in preferences for long-acting injectable PrEP among US men who have sex with men: A latent class analysis. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. On-Demand Oral Abstract.
CUSTOMIZE: Overall results from a hybrid III implementation-effectiveness study examining implementation of cabotegravir and rilpivirine long-acting injectable (CAB+RPV LA) for HIV treatment in US healthcare settings; final patient and provider data. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. On-Demand Oral Abstract.
CAB+RPV LA implementation outcomes and acceptability of monthly clinic visits improved during COVID-19 pandemic across US healthcare clinics (CUSTOMIZE: Hybrid III Implementation-Effectiveness Study). Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. E-Poster.
Week 124 results of the randomized, open-label, phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population). Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. On-Demand Oral Abstract.
High interest in long-acting injectable HIV pre-exposure prophylaxis among nationwide sample of men who have sex with men in the US: AMIS 2019. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. E-Poster.
Clinical outcomes during CUSTOMIZE: a hybrid III implementation-effectiveness study focused on implementation of cabotegravir plus rilpivirine (CAB+RPV) LA in US healthcare settings. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. E-Poster.
Integrase strand transfer inhibitor (INSTI) use and cancer incidence. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. E-Poster.
Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA). Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. Oral Presentation.
Feasibility, Efficacy, and Safety of Dolutegravir/Lamivudine (DTG/3TC) as a First-line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living With HIV (PLWH): 48-Week Results of the STAT Study. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. E-Poster.
DTG+3TC in GEMINI-1&-2: HIV-1 replication at <50 c/mL and VL blips through 144 weeks. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. E-Poster.
Metabolic health outcomes at week 144 in the TANGO Study, comparing a switch to DTG/3TC versus maintenance of TAF-based regimens. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. E-Poster.
Comparison of Viral Replication for the 2-Drug Regimen (2DR) of Dolutegravir/Lamivudine (DTG/3TC) versus a 3/4-Drug Tenofovir Alafenamide-based regimen (TBR) in the TANGO Study through Week 96. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. On-Demand Oral Abstract.
Antiretroviral agents used in optimized background therapy with fostemsavir in heavily treatment-experienced adults with HIV-1: exploratory analyses of the phase 3 BRIGHTE study. Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. E-Poster.
Long-term (96 week) safety of fostemsavir (FTR) in heavily-treatment experienced (HTE) adults infected with multi-drug resistance (MDR) HIV-1 (BRIGHTE phase 3 study). Presented at the 11th IAS Conference on HIV Science, July 18-21, 2021, Virtual Event. E-Poster.
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.
My MSL
Enter zip code to find your MSL contact.
This site uses cookies and similar technologies (collectively, "cookies") to enhance your website experience and track the site's performance. These cookies are automatically enabled. By using this site, you agree to our use of these cookies in accordance with our Privacy Notice. Click on Privacy Choices below to manage your preferences, including to opt out of the sale or sharing of your information.
Managing Privacy Options
OPT OUT OF SALE AND SHARING OF INFORMATION
Your state law may allow you the right to opt out of the sale or sharing of your personal information for targeted advertising. You may opt out of such sale or share via the toggle available to you for "Targeting Cookies," and selecting the "Confirm my choices” button below. To limit sale or sharing of your information for targeting advertising offline, please see the "Cookies and Targeted Advertising Choices," section in the Privacy Notice and submit the required form.
Always Active
Necessary for the website to function appropriately, such as to store session data during a website visit, to manage cookie and tag preferences, and to protect the security of the website. In addition, some of these cookies are set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms.
Always Active
Enable the website to provide enhanced functionality and personalization, such as by helping us to measure how many visitors come to our websites, what sites our website visitors come from, and how often certain pages on our website are viewed. These cookies may be set by us or by third party providers, like our analytics service providers, whose services we have added to our pages.
Allow us to target and re-target you with relevant advertising. We and our advertising partners use information collected through these technologies to infer your interests in order to serve you more relevant advertisements on other sites. If you don’t allow these cookies, you will receive advertising, but it may be less relevant to you.
